-
Biotin-tyramide for Reliable Spatial Assays
2026-09-13
Learn how Biotin-tyramide (SKU A8011) supports enzyme-mediated signal amplification in immunohistochemistry and in situ hybridization workflows that complement cell viability, proliferation, and cytotoxicity assays. The guide emphasizes solvent handling, controls, interpretation, and practical vendor-selection criteria.
-
Cyclosporin A (B1922): Practical Lab Workflow
2026-09-12
Cyclosporin A (B1922) supports controlled cyclophilin and calcineurin-NFAT pathway studies in biochemical and cellular models, including immune activation, apoptosis modulation, and mitochondrial function. It should be prepared in an organic solvent rather than water, with solvent-matched controls and model-specific dose validation; the product should not be treated as a ready-made aqueous reagent or a clinical dosing reference.
-
ANKLE2 Promotes Zika Virus Replication
2026-09-11
Fishburn and colleagues show that the microcephaly-associated host protein ANKLE2 acts as a proviral factor for Zika virus by supporting virus-induced endoplasmic reticulum remodeling. The effect extends to mosquito cells and other orthoflaviviruses, linking ANKLE2-dependent membrane organization with viral replication and immune evasion.
-
Stabilizing LNP Self-Replicating RNA Vaccines
2026-09-11
The reference study systematically examines how temperature, buffer composition, cryoprotection, and lyophilization affect lipid nanoparticle-formulated self-replicating RNA vaccines. Its central finding is that an RNase-free PBS formulation containing 10% (w/v) sucrose preserved structural integrity and in vivo potency at −20 °C for 30 days, while lyophilization also retained bioactivity under the tested conditions.
-
Dinaciclib Synthetic Lethality in VHL-Deficient RCC
2026-09-10
The reference study identifies a selective vulnerability in clear cell renal cell carcinoma (CC-RCC): loss of VHL increases dependence on cell-cycle-associated survival programs that can be disrupted by the CDK inhibitor Dinaciclib. Using cellular assays and an orthotopic patient-derived xenograft model, the authors show activity against both CD105-positive cancer stem cells and CD105-negative tumor cells while defining important limits related to proliferation state and genotype.
-
SB 431542: Practical ALK5 Inhibitor Workflows
2026-09-10
SB 431542 enables controlled interrogation of ALK5-driven TGF-β signaling, from Smad2 phosphorylation assays to CD44 regulation in breast cancer stem-like cells. Its value is strongest when pathway inhibition is paired with orthogonal genetic, phenotypic, and immune readouts rather than used as a standalone cytotoxicity test.
-
Cefodizime in Translational Infection Models
2026-09-09
Cefodizime offers translational researchers a mechanistically defined way to connect penicillin-binding protein inhibition, antimicrobial resistance surveillance, host-response biology, and exposure-aware infection modeling.
-
MDL 28170: A Practical Calpain Inhibitor Workflow
2026-09-09
MDL 28170 is a membrane-permeable calpain inhibitor designed for mechanistic studies spanning hippocampal injury, apoptosis assay workflows, and cysteine-protease biology. Its brain penetration, nanomolar biochemical potency, and activity against both calpain and cathepsin B make it useful for target-engagement experiments, provided researchers separate calpain-specific conclusions from broader cysteine-protease effects.
-
Hexamethonium Bromide in Autonomic Signaling
2026-09-08
Hexamethonium Bromide enables functional interrogation of autonomic ganglia by selectively interrupting neuronal nicotinic acetylcholine receptor signaling. This guide translates sex-aware hypertension findings into practical telemetry, ex vivo, and troubleshooting workflows without confusing ganglionic blockade with a complete measure of sympathetic activity.
-
Gentamycin Sulfate in Resistance Research
2026-09-08
Learn how to use Gentamycin Sulfate to connect ribosome inhibition with susceptibility testing, plasmid analysis, and carbapenemase transmission studies. The workflow emphasizes orthogonal validation so a gentamycin phenotype is not mistaken for proof of a specific resistance gene.
-
CA-074 Me in Lysosomal Cell Death Research
2026-09-07
CA-074 Me enables cell-permeable interrogation of cathepsin B during lysosomal membrane permeabilization, necroptosis, and apoptosis assays. Its strongest advantage is mechanistic placement: researchers can test whether cathepsin B is a downstream driver rather than merely a marker of lysosomal damage.
-
Calpain, BDNF/TrkB, and Offspring Cognition
2026-09-07
A 2025 Neuropharmacology study links maternal non-obstetric surgery during pregnancy to later offspring cognitive impairment through excessive calpain activity and suppression of hippocampal BDNF/TrkB signaling. Postnatal treatment with the calpain inhibitor MDL 28170 or the TrkB agonist 7,8-DHF partially rescued molecular, structural, and behavioral deficits, supporting calpain–TrkB dysregulation as a mechanistic target for neuroprotection research.
-
Omega-3 PUFAs Protect Against Cisplatin Nephrotoxicity
2026-09-05
The reference study shows that combined EPA and DHA protect mice and renal tubular epithelial cells from cisplatin-induced injury more effectively than either fatty acid alone. Its mechanistic contribution is the linkage of p62-Keap1-Nrf2 antioxidant signaling with MDM2-p53 apoptosis control, including reduced inflammation and chronic renal fibrosis after repeated CDDP exposure.
-
MLKL Polymerization and Lysosomal Membrane Permeabilization
2026-09-04
The reference study identifies lysosomal membrane permeabilization as a direct downstream consequence of MLKL polymerization during necroptosis. Its experiments place lysosomal cathepsin B release before plasma membrane rupture and show that cathepsin B inhibition or depletion can protect cells, providing a mechanistic framework for studying lysosomal protease activity in regulated cell death.
-
nor-NOHA Acetate: Arginase Research Workflows
2026-09-04
Build reproducible enzyme, cancer-cell, and vascular assays around nor-NOHA acetate, a reversible arginase inhibitor that redirects arginine metabolism. This workflow also shows how to position arginase experiments beside emerging lipid-driven immune-escape studies without overstating the evidence.